PARP1 and cancer: Preclinical and clinical efficacy of DDR inhibition in cells with a defective DDR genetic background, are exemplified by the success of PARP inhibitors in BRCA1/2-mutated advanced cancers and of inhibitors to the PARG in cancer cells (261, 266, 267).